Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
South Korea, US Discuss Warship Building Cooperation 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
H&M Q3 Profit Beats Estimates as Margins Improve 
Wall Street Falls as Treasury Yields Surge, Oil Rebounds on Iran Tensions 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
Goldman Sachs Names Simon Lyons UK Investment Banking Co-Head 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Trump Plans Federal AI Force and AI Czar 
China Vanke Shares Jump as Beijing Moves to Ease Debt Pressure 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI 
Novo Nordisk Weighs Direct NYSE Listing to Boost U.S. Profile 
Add as a preferred source on Google
Celltrion Healthcare will bring its parent company’s adalimumab biosimilar called Yuflyma to Europe next month. The company is in charge of Celltrion’s businesses overseas, and it will be launching the said biosimilar drug and start its sale in European countries.
The launch of Yuflyma
As per The Korea Herald, Celltrion will introduce Yuflyma in six European regions at first. A company official reportedly said that they will attempt to release the product in Spain this coming June, but this date could still change.
Celltrion’s Yuflyma is said to be the world’s first biosimilar of Humira, the original drug containing adalimumab and made by AbbVie pharmaceutical company, a spin-off of Abbott Laboratories.
In the third quarter of this year, Celltrion Healthcare is aiming to launch the drug in seven additional European countries and will include France and Germany. In the last quarter, it will roll out in three more regions, including Italy.
Approval of Celltrion’s Biosimilar
The European Commission handed down the authorization for Yuflyma in February. The agency approved it for use in Europe for the treatment of patients suffering from 13 chronic inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, pediatric uveitis, juvenile idiopathic arthritis, and ulcerative colitis.
Celltrion Healthcare shared that the company was given the EU marketing authorization for the high-concentration, citrate-free adalimumab biosimilar. It will be sold under the Yuflyma brand name, which was called the CT-P17 when it was still being developed.
The citrate-free and high concentration formulation, which is 100mg/mL, was applied to lessen the dosage of the existing drug by half. In comparison, most of the Humira biosimilars have low concentrations of the drug.
The Center for Biosimilars stated that the approval is notable because even if the European market has many adalimumab biosimilars already, this one coming from Celltrion has no citrate, a substance that is said to make the drug administration painful for patients. Apparently, it was removed to avoid pain.
Celltrion’s entrance into the adalimumab manufacturing also makes it the first to compete in this new market but with a lower-cost biosimilar. Meanwhile, the approval from the EU commission was followed by positive opinions from the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP).
